Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 62

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 62
---
 deducting offering expenses in the amount
of approximately $0.1 million.

In
January 2025, we completed a private placement (the “January 2025 Financing”) for the sale and issuance by us of an aggregate
of: (i) 75,335 shares of our common stock and (ii) warrants to purchase 75,335 shares of common stock. The shares and warrants were sold
on a combined basis for consideration of $29.82 for one share and one warrant for aggregate gross proceeds of approximately $2.25 million.

In
June 2022, we entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022
with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock, par value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The
issuance and sale of common stock by us under the ATM Agreement is being made pursuant to our effective “shelf” registration
statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective on September 9, 2022. In 2024, we sold 5,428 shares
of our common stock for aggregate gross proceeds of approximately $0.4 million. On August 6, 2024, we filed a prospectus supplement to
reduce the amount of shares registered under the prospectus for the ATM to $0.00 and to suspend the ATM program, but the ATM Agreement
remains in full force and effect.

We
believe that our cash and cash equivalents of approximately $6.2 million that we had as of June 30, 2025 will enable us to fund our
operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on our current operating plan. We will
need to increase our capital resources through equity or debt financings, and we may need to do so sooner than we expect. We may
also seek to finance our cash needs through collaborations, strategic alliances, or license agreements with third parties. If
sources of financing are available, they may result in substantial dilution to our stockholders. We cannot provide any assurance
that new financing will be available to us on commercially acceptable terms or in the amounts required, if